Amino Acid, Peptide, or Protein

German cancer antibody biotech eyes SPAC as route to Nasdaq

15 hours ago talkbio0Tagged Antibodies, German language, Nasdaq, SPAC, Veraxa

Veraxa, Antibodies, SPAC, German language, Nasdaq

Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug

2 days ago talkbio0Tagged Approved, competition, eli lilly, Glucagon-Like Peptide 1, Market, Nordisk, Novo, Obesity, Oral cavity, Pressure- physical agent, semaglutide, United States Food and Drug Administration

Nordisk, Obesity, Approved, Oral cavity, Glucagon-Like Peptide 1, Market, Pressure- physical agent, eli lilly, competition, Novo, semaglutide, United States Food and Drug Administration, United States Food and Drug Administration

Gilead eyes earlier use of Trodelvy in TNBC as Phase III hits key goal

2 days ago talkbio0Tagged Keytruda, Metastatic to, Overall Survival, Triple Negative Breast Neoplasms, Trodelvy

Trodelvy, Triple Negative Breast Neoplasms, Metastatic to, Keytruda, Overall Survival

AstraZeneca, Daiichi say Enhertu delivers ‘highly statistically significant’ efficacy in first-line breast cancer

3 days ago talkbio0Tagged Antibodies, Antibody-Drug Conjugates, AstraZeneca, Daiichi, deruxtecan-nxki, Enhertu, fam-trastuzumab, first-line therapy, HER2-positive metastatic breast cancer, pertuzumab, Progression-Free Survival, Sankyo

Enhertu, fam-trastuzumab deruxtecan-nxki, AstraZeneca, Daiichi Sankyo, HER2-positive metastatic breast cancer, first-line therapy, progression-free survival, antibody drug conjugate (ADC), pertuzumab

Stealth biotech bags rights to VelaVigo bispecific in $440M deal

6 days ago talkbio0Tagged Antibodies, Bispecific, China, stealth, VelaVigo

VelaVigo, Antibodies, Bispecific, stealth, China

UK approval brings GSK’s Blenrep back from the brink

6 days ago talkbio0Tagged Antibody-Drug Conjugates, Approved, Blenrep, Cessation of life, dexamethasone, DREAMM-8, Multiple Myeloma, Risk, UK

UK, Approved, Multiple Myeloma, DREAMM-8, dexamethasone, Blenrep, Antibody-Drug Conjugates, Risk, Cessation of life

Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss

6 days ago talkbio0Tagged Diabetes Mellitus, Non-Insulin-Dependent, Glucagon-Like Peptide 1, Hemoglobin A1c measurement, Injectables, Oral cavity, orforglipron, Phase 3 Clinical Trials, Safety, Weight Loss

orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables

Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology

7 days ago talkbio0Tagged Antibodies, Bispecific, Autoimmune, Collaboration, development aspects, Earendil Labs, Immunology, Inflammatory Bowel Diseases, sanofi

Antibodies, Bispecific, Autoimmune, Inflammatory Bowel Diseases, sanofi, Earendil Labs, Immunology, Collaboration, development aspects

RFK Jr. attacks environmental toxins as cause of childhood autism ‘epidemic’, stays silent on vaccines

7 days ago talkbio0Tagged Autistic Disorder, Environment, HHS, Kennedy, RFK gene, Vaccines

Autistic Disorder, Vaccines, Kennedy, Environment, RFK gene, HHS

HHS Terminates Funding for GeoVax’s Next-Generation COVID-19 Vaccine: Impacts and Developments

7 days ago talkbio0Tagged BARDA, CHARGE Syndrome, Clinical Trials, COVID19 (disease), development aspects, GeoVax, Immunocompromised Host, pandemic preparedness, Project NextGen, Termination - Inactive Reason Code, Vaccines

GeoVax, HHS, BARDA, Project NextGen, COVID-19 vaccine, GEO-CM04S1, clinical trials, funding termination, immunocompromised, vaccine development, pandemic preparedness